Cartesian Therapeutics (RNAC) Net Margin (2016 - 2025)
Historic Net Margin for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to 4318.14%.
- Cartesian Therapeutics' Net Margin fell 4416600.0% to 4318.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 4620.62%, marking a year-over-year decrease of 41737600.0%. This contributed to the annual value of 198.97% for FY2024, which is 6459400.0% up from last year.
- According to the latest figures from Q3 2025, Cartesian Therapeutics' Net Margin is 4318.14%, which was down 4416600.0% from 4448.99% recorded in Q2 2025.
- Over the past 5 years, Cartesian Therapeutics' Net Margin peaked at 4448.99% during Q2 2025, and registered a low of 4318.14% during Q3 2025.
- Moreover, its 5-year median value for Net Margin was 71.1% (2021), whereas its average is 295.37%.
- Within the past 5 years, the most significant YoY rise in Cartesian Therapeutics' Net Margin was 55776700bps (2024), while the steepest drop was -37390700bps (2024).
- Quarter analysis of 5 years shows Cartesian Therapeutics' Net Margin stood at 40.88% in 2021, then decreased by -14bps to 35.09% in 2022, then tumbled by -6880bps to 2379.12% in 2023, then surged by 234bps to 3198.55% in 2024, then plummeted by -235bps to 4318.14% in 2025.
- Its Net Margin was 4318.14% in Q3 2025, compared to 4448.99% in Q2 2025 and 1806.73% in Q1 2025.